Woodline Partners LP decreased its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 85.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,190 shares of the company's stock after selling 159,919 shares during the period. Woodline Partners LP's holdings in DaVita were worth $3,917,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of DVA. Epoch Investment Partners Inc. acquired a new position in DaVita during the 4th quarter valued at about $55,100,000. Invesco Ltd. increased its stake in DaVita by 20.9% during the 4th quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock valued at $237,716,000 after buying an additional 275,284 shares during the period. Iron Triangle Partners LP acquired a new position in DaVita during the 4th quarter valued at about $38,946,000. Amundi increased its stake in DaVita by 116.4% during the 4th quarter. Amundi now owns 446,386 shares of the company's stock valued at $68,726,000 after buying an additional 240,126 shares during the period. Finally, Bridgewater Associates LP grew its stake in shares of DaVita by 298.4% in the 4th quarter. Bridgewater Associates LP now owns 239,970 shares of the company's stock worth $35,888,000 after purchasing an additional 179,744 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on DVA shares. Barclays lifted their price objective on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th. Truist Financial lowered their price objective on shares of DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a research note on Monday, May 19th. Cowen reaffirmed a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. Finally, Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $164.50.
Get Our Latest Research Report on DVA
DaVita Trading Up 0.2%
Shares of DVA traded up $0.27 during midday trading on Friday, hitting $136.60. The stock had a trading volume of 121,419 shares, compared to its average volume of 819,148. DaVita Inc. has a fifty-two week low of $131.76 and a fifty-two week high of $179.60. The business has a 50-day simple moving average of $144.38 and a two-hundred day simple moving average of $153.00. The firm has a market cap of $10.31 billion, a P/E ratio of 12.73, a price-to-earnings-growth ratio of 1.07 and a beta of 1.14. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18.
DaVita (NYSE:DVA - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported $2.00 EPS for the quarter, topping the consensus estimate of $1.75 by $0.25. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The company had revenue of $3.22 billion during the quarter, compared to analysts' expectations of $3.22 billion. During the same period last year, the company posted $2.26 earnings per share. The business's revenue for the quarter was up 5.0% on a year-over-year basis. As a group, equities analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.
DaVita Profile
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
See Also
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
